Europe faces a pivotal moment in its ability to provide essential medicines to its citizens. The Critical Medicines Act (CMA) was designed as a transformative policy to address recurring shortages and reduce dependency on non-EU suppliers. However, current legislative discussions are threatening to severely dilute its impact.

We urge the European Parliament and Council to vote for a robust, enforceable Critical Medicines Act. This legislation must restore Europe’s strategic autonomy, support its industrial base, and ensure reliable access to essential medicines for all EU citizens. The recommendations of the Critical Medicines Alliance must be fully integrated, sending a clear signal that Europe is committed to sustaining and investing in its medicines supply chain. This is not only an industrial imperative—it is a moral obligation to all EU patients and the healthcare community.